Targeting Innate Immunity for CV Benefit. - Wikidata - wikimedia - TriplyDB

Targeting Innate Immunity for CV Benefit.

Targeting Innate Immunity for CV Benefit.

http://www.wikidata.org/entity/Q37476718

about

High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

P2860

Q34334697-E49828B4-FE28-435F-9C26-A4FF7C86EEED

P2860

Targeting Innate Immunity for CV Benefit.

http://www.wikidata.org/entity/Q37476718

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting Innate Immunity for CV Benefit.

@en

Targeting Innate Immunity for CV Benefit.

@nl

type

label

Targeting Innate Immunity for CV Benefit.

@en

Targeting Innate Immunity for CV Benefit.

@nl

prefLabel

Targeting Innate Immunity for CV Benefit.

@en

Targeting Innate Immunity for CV Benefit.

@nl

P1433

Q37476718-F66F5FDB-5466-43C7-9574-B9BD86A444FB

P1476

Q37476718-961406F2-AFE5-44C0-910E-E2A43FEF929F

P2093

Q37476718-6AF26D36-35DB-449E-925D-9B85DF81452B

Q37476718-E3085218-8D88-4A8E-ADD6-7A6073230AEA

P2860

Q37476718-006D582F-A648-4735-A670-B3932A18DBEB

Q37476718-04A4F075-3094-406F-8E59-419BC274B89B

Q37476718-107A7003-83F3-4C60-B993-482EC3FFCDB6

Q37476718-1EBF15FC-72DF-4176-A4C0-44B0A44CCCB7

Q37476718-2132FCDD-636A-464D-B89C-0DD3020DA000

Q37476718-27B8FA4D-34CF-4D2F-BA49-07E81F2E7F36

Q37476718-32377318-DB3A-463A-9905-4EC8A4AC7A95

Q37476718-37D3E9CE-F62D-454C-AF0B-8F7EBEFD3BEA

Q37476718-3AF5ECD1-EA0E-4954-90EA-E78F1FEC2929

Q37476718-4BFF3DD2-52AD-4899-AF5E-5F876896CC4C

P304

Q37476718-7FA8CC77-763A-4CF9-ACFF-0A1A41B07FDA

P31

Q37476718-C4759113-89D7-4B14-82BE-3F944160D865

P356

Q37476718-02B8F44F-9ACE-46A1-B829-2C05A3490BC5

P433

Q37476718-F89FEE0A-60CB-4736-B6F4-86BE96F97200

P478

Q37476718-770717A7-8050-4072-B89E-94B41614AF8E

P577

Q37476718-09C48881-7019-4F63-B68B-6DB455E317C0

P698

Q37476718-8BD0FB8E-7598-441D-A47C-3127DF7B4236

P932

Q37476718-07504992-5EF3-4D96-A082-3928D982C50F

P356

J.DDSTR.2008.05.007

P1433

Drug Discovery Today: Therapeutic Strategies

P1476

Targeting Innate Immunity for CV Benefit.

@en

P2093

Kathryn J Moore

http://www.w3.org/2001/XMLSchema#string

Mason W Freeman

http://www.w3.org/2001/XMLSchema#string

P2860

Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages

Toll-like receptor signalling

Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice

Atherosclerosis

Atherosclerosis — An Inflammatory Disease

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

Effect of torcetrapib on the progression of coronary atherosclerosis

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity

Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain

P304

15-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DDSTR.2008.05.007

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19430537

http://www.w3.org/2001/XMLSchema#string

P932

2678718

http://www.w3.org/2001/XMLSchema#string